SEARCH:   Advanced

Blood, 1 July 2004, Vol. 104, No. 1, pp. 143-148. Prepublished online as a Blood First Edition Paper on March 16, 2004; DOI 10.1182/blood-2003-11-4085. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-11-4085v1 104/1/143    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Brouwer, J.-L. P. Articles by van der Meer, J. Search for Related Content PubMed PubMed Citation Articles by Brouwer, J.-L. P. Articles by van der Meer, J. Related Collections Hemostasis, Thrombosis, and Vascular Biology Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus Jan-Leendert P. Brouwer, Marc Bijl, Nic J. G. M. Veeger, Hanneke C. Kluin-Nelemans, and Jan van der Meer From the Division of Haemostasis, Thrombosis and Rheology, Department of Hematology; the Department of Immunology; and the Trial Coordination Centre, University Hospital Groningen, the Netherlands. Systemic lupus erythematosus (SLE) is associated with an increased risk of venous (VTE) and arterial thromboembolism (ATE). Lupus anticoagulant (LA) and anticardiolipin antibodies (ACAs) are established risk factors. We assessed the contribution of deficiencies of antithrombin, protein C, total protein S, factor V Leiden, the prothrombin G20210A mutation and APC resistance, either alone or in various combinations with LA and/or ACAs, to the thrombotic risk in a cohort of 144 consecutive patients with SLE. Median follow-up was 12.7 years. VTE had occurred in 10% and ATE in 11% of patients. LA,ACAs, factor V Leiden, and the prothrombin mutation were identified as risk factors for VTE. Annual incidences of VTE were 2.01 (0.74-4.37) in patients with one of these disorders and 3.05 (0.63-8.93) in patients with 2 disorders. The risk of VTE was 20- and 30-fold higher, respectively, compared with the normal population. In contrast with LA and ACAs, thrombophilic disorders did not influence the risk of ATE. In conclusion, factor V Leiden and the prothrombin mutation contribute to the risk of VTE in patients with SLE, and potentiate this risk when one of these thrombophilic defects are combined with LA and/or ACAs. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. DANOWSKI, M. N. L. de AZEVEDO, J. A. de SOUZA PAPI, and M. PETRI Determinants of Risk for Venous and Arterial Thrombosis in Primary Antiphospholipid Syndrome and in Antiphospholipid Syndrome with Systemic Lupus Erythematosus J Rheumatol, June 1, 2009; 36(6): 1195 - 1199. [Abstract] [Full Text] [PDF] M. K. Farmer-Boatwright and R. A.S. Roubey Venous Thrombosis in the Antiphospholipid Syndrome Arterioscler. Thromb. Vasc. Biol., March 1, 2009; 29(3): 321 - 325. [Abstract] [Full Text] [PDF] W. M. Lijfering, R. Mulder, M. K. ten Kate, N. J. G. M. Veeger, A. B. Mulder, and J. van der Meer Clinical relevance of decreased free protein S levels: results from a retrospective family cohort study involving 1143 relatives Blood, February 5, 2009; 113(6): 1225 - 1230. [Abstract] [Full Text] [PDF] J. ROMERO-DIAZ, I. GARCIA-SOSA, and J. SANCHEZ-GUERRERO Thrombosis in Systemic Lupus Erythematosus and Other Autoimmune Diseases of Recent Onset J Rheumatol, January 1, 2009; 36(1): 68 - 75. [Abstract] [Full Text] [PDF] G. W. Moore, S. Rangarajan, and G. F. Savidge The Activated Seven Lupus Anticoagulant Assay Detects Clinically Significant Antibodies Clinical and Applied Thrombosis/Hemostasis, July 1, 2008; 14(3): 332 - 337. [Abstract] [PDF] W. M. Lijfering, H. G. Sprenger, R. R. Georg, P. A. van der Meulen, and J. van der Meer Relationship between Progression to AIDS and Thrombophilic Abnormalities in HIV Infection Clin. Chem., July 1, 2008; 54(7): 1226 - 1233. [Abstract] [Full Text] [PDF] K. de Leeuw, R. Graaff, R. de Vries, R. P. Dullaart, A. J. Smit, C. G. Kallenberg, and M. Bijl Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus Rheumatology, October 1, 2007; 46(10): 1551 - 1556. [Abstract] [Full Text] [PDF] Z. Touma, S. Atweh, L. Kibbi, and T. Arayssi Longitudinal myelitis in patient with systemic lupus erythematosus, homozygous prothrombin G20210A and heterozygous MTHFR 677T Lupus, July 1, 2007; 16(7): 517 - 520. [Abstract] [PDF] T. Lecompte, D. Wahl, C. Perret-Guillaume, H. C. Hemker, P. Lacolley, and V. Regnault Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk Haematologica, May 1, 2007; 92(5): 714 - 715. [Abstract] [Full Text] [PDF] K De Leeuw, B Freire, A J Smit, H Bootsma, C G Kallenberg, and M Bijl Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus Lupus, October 1, 2006; 15(10): 675 - 682. [Abstract] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020